Masahiko Aoki
Osaka Medical College
12 Papers
16 Citations
Masahiko Aoki is an academic researcher from Osaka Medical College. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination
Norihide Jo,Yumi Hidaka,Osamu Kikuchi,Masaru Fukahori,Takashi Sawada,Masahiko Aoki,Masayuki Yamamoto,Miki Nagao,Satoshi Morita,Takako Nakajima,Manabu Muto,Yoko Hamazaki +11 more
TL;DR: In this paper , older adults had fewer vaccine-induced spike-specific CD4 + T cells including CXCR3 + circulating follicular helper T cells and the T H 1 subset of T cells after the first dose, which correlated with their lower peak IgG levels and fewer systemic adverse effects after the second dose compared with younger adults.
Novel Therapeutic Approach Using Drug-loaded Adipose-derived Stem Cells for Pancreatic Cancer
TL;DR: The present therapeutic strategy might give rise to a novel cancer therapy minimizing the adverse side effects of anticancer drugs in patients who suffer from cancer.
Small-cell Lung Cancer in a Young Adult Nonsmoking Patient with Ectopic Adrenocorticotropin (ACTH) Production.
Masahiko Aoki,Yasuhito Fujisaka,Satoshi Tokioka,Ai Hirai,Yujiro Henmi,Yosuke Inoue,Ken Narabayashi,Takeshi Yamano,Yosuke Tamura,Yutaro Egashira,Kazuhide Higuchi +10 more
TL;DR: The physical findings, including proximal myopathy, truncal obesity and pigmentation suggested high levels of glucocorticoids, and an endocrinological investigation allowed for the definitive diagnosis of SCLC with ectopic ACTH production.
8
Impact of modified FOLFOX-6 for patients with gastric cancer and a gastrointestinal obstruction.
Hiroki Yukami,Tetsuji Terazawa,Masahiro Goto,Masahiko Aoki,Ken Asaishi,Toshifumi Yamaguchi,Shin Kuwakado,Takayuki Kii,Kazuhide Higuchi +8 more
TL;DR: The aim of this study was to assess the efficacy of mFOLFOX‐6 for gastric cancer patients with a gastrointestinal obstruction.
5
Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Hiroyuki Kodama,Tetsuji Terazawa,Yasunobu Ishizuka,Hiroki Yukami,Masahiko Aoki,Takahiro Miyamoto,Toshifumi Yamaguchi,Futukaro Shimamoto,Takayuki Kii,Masahiro Goto,Hiroki Hamamoto,Wataru Osumi,Masashi Yamamoto,Keitaro Tanaka,J. Okuda,Kazuhisa Uchiyama,Kazuhide Higuchi +16 more
TL;DR: In this article, the efficacy and safety of oxaliplatin, irinotecan, folinic acid, and 5-fluorouracil (mFOLFOXIRI) with capecitabine/S-1 and oxalplatin (XELOX/SOX) for locally advanced rectal cancer patients were compared.
3